Minretumomab

In today's world, Minretumomab is an issue that has gained great relevance in society. As time progresses, we find the need to explore and understand this Minretumomab from different perspectives. The importance of Minretumomab cannot be underestimated as it affects various aspects of daily life. Therefore, it is crucial to address this issue completely and objectively to understand its impact on today's society. In this article, we will analyze in detail Minretumomab and its influence in diverse contexts, in order to offer a comprehensive and updated vision of this very relevant topic.

Minretumomab
Monoclonal antibody
TypeWhole antibody
SourceMouse
TargetTAG-72
Clinical data
Other namesCC49
ATC code
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Minretumomab (CC49) is a mouse monoclonal antibody[1] that was designed for the treatment of cancers that express the TAG-72 antigen. This includes breast, colon, lung, and pancreatic cancers.[2][3] Apparently, it never got past Phase I clinical trials for this purpose.[4]

Derivatives

A wide range of derivatives has been used in pharmaceutical research. Examples include chimeric[5] and humanized minretumomab,[6] as well as a fusion protein of a minretumomab single-chain variable fragment and the enzyme beta-lactamase.[7]

Radiopharmaceuticals

Iodine (125I) minretumomab is an iodine-125 radiolabelled derivative that was developed for the detection of tumours in radioimmunoassays such as CA 72-4.[8]

Radiolabelled minretumomab has also been tested for the treatment of solid tumours, but without success. Iodine (131I) and lutetium (177Lu) minretumomab, for example, were shown to induce human anti-mouse antibodies; no tumour response was observed in Phase I and II clinical trials.[5]

References

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 13 (3). 1999.
  2. ^ "TAG-72 antigen". NCI Dictionary of Cancer Terms. National Cancer Institute. 2011-02-02.
  3. ^ Scott AM, Wolchok JD, Old LJ (March 2012). "Antibody therapy of cancer". Nature Reviews. Cancer. 12 (4): 278–87. doi:10.1038/nrc3236. PMID 22437872. S2CID 205469234.
  4. ^ "Studies found for: CC49". ClinicalTrials.gov.
  5. ^ a b Trahan Rieger P, ed. (2001). Biotherapy (2nd ed.). Jones and Bartlett. pp. 334–335. ISBN 0-7637-1428-3.
  6. ^ Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW (February 2010). "Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72". Cancer. 116 (4 Suppl): 1059–66. doi:10.1002/cncr.24793. PMC 4498458. PMID 20127951.
  7. ^ Alderson RF, Toki BE, Roberge M, Geng W, Basler J, Chin R, et al. (2006). "Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT)". Bioconjugate Chemistry. 17 (2): 410–8. doi:10.1021/bc0503521. PMID 16536473.
  8. ^ Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Tedesco M, et al. (November 1996). "Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay". Cancer Research. 56 (22): 5293–8. PMID 8912871.
Wikious
Boobota
Sagapedia